pomalidomide has been researched along with Lymphoma, B-Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, N; Gao, H; Hwang, J; Liu, W; Rao, Y; Song, Y; Sun, Y; Wu, Y; Yang, Y; Zhao, M; Zhao, X | 1 |
| Brady, HA; Chan, KW; Chen, R; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Lopez-Girona, A; Moutouh-de Parseval, L; Mueller, JH; Muller, GW; Schafer, PH; Verhelle, D; Wong, K | 1 |
2 other study(ies) available for pomalidomide and Lymphoma, B-Cell
| Article | Year |
|---|---|
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; HEK293 Cells; HeLa Cells; Humans; Lymphoma, B-Cell; Mutation; Piperidines; Protein Domains; Proteolysis; Pyrazoles; Pyrimidines; Thalidomide | 2018 |
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Topics: Antigens, CD34; Antineoplastic Agents; B-Lymphocytes; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Hematopoietic Stem Cells; Humans; Lenalidomide; Lymphoma, B-Cell; Phosphorylation; Retinoblastoma Protein; Thalidomide; Up-Regulation | 2007 |